Last updated: September 3, 2026
Neomycin sulfate and polymyxin B sulfate are mature, low-cost antibacterial ingredients used mainly in ophthalmic, otic, and topical combination products. The market is genericized, fragmented, and price-sensitive. Revenue growth is unlikely to come from volume expansion or patent exclusivity. Financial performance depends on manufacturing cost, supply reliability, formulary access, retail distribution, and temporary shortages.
The active ingredients have long-established FDA histories. Neomycin is an aminoglycoside antibiotic, while polymyxin B is a polypeptide antibiotic active against selected gram-negative organisms. Products containing both ingredients are commonly sold as ophthalmic ointments or solutions and in otic combinations with hydrocortisone or other corticosteroids.[1-4]
What products contain neomycin sulfate and polymyxin B sulfate?
The combination is marketed through several dosage forms rather than as a single branded franchise.
| Product type |
Typical active ingredients |
Main use |
U.S. regulatory position |
| Ophthalmic ointment |
Neomycin sulfate and polymyxin B sulfate, sometimes with bacitracin zinc |
Bacterial eye infections and prophylaxis |
Generic prescription product |
| Ophthalmic solution |
Neomycin sulfate and polymyxin B sulfate, sometimes with dexamethasone |
Bacterial ocular inflammation and infection |
Generic prescription product |
| Otic solution or suspension |
Neomycin sulfate and polymyxin B sulfate, usually with hydrocortisone |
Bacterial external ear infections |
Generic prescription product |
| Topical cream or ointment |
Neomycin with polymyxin B, often with bacitracin or other ingredients |
Minor skin wounds and infection prevention |
Prescription and nonprescription variants, depending on formulation |
The exact commercial market differs materially by dosage form. Ophthalmic products are prescription products with sterile-manufacturing requirements. Otic products compete in a broader market that includes corticosteroid combinations and non-antibiotic treatments. Topical products face intense private-label and retail competition.
What is the FDA regulatory status of neomycin and polymyxin B products?
FDA-approved products containing neomycin sulfate and polymyxin B sulfate are legacy anti-infective products. Their regulatory value comes from established clinical use and manufacturing capability, not from market exclusivity.
Ophthalmic products
Ophthalmic ointments and solutions require sterile production, validated filling processes, container-closure controls, and testing for particulate matter, sterility, potency, and preservative performance where applicable. These requirements raise manufacturing barriers relative to ordinary topical creams.[1][2]
Some products combine the antibiotics with bacitracin zinc. Others combine them with a corticosteroid such as dexamethasone. Combination products with corticosteroids carry additional prescribing and safety considerations, including the risk that steroid use can worsen or mask certain infections.[2]
Otic products
The common otic formulation contains neomycin sulfate, polymyxin B sulfate, and hydrocortisone. The product is indicated for susceptible bacterial infections of the external auditory canal. Neomycin-related sensitization and ototoxicity warnings are important factors in product selection and labeling.[3]
FDA approval pathway
New entrants generally rely on abbreviated new drug applications for products that can demonstrate pharmaceutical equivalence and bioequivalence to an approved reference product. The competitive advantage therefore depends on identifying a suitable reference listed drug, matching the dosage form, and satisfying quality and sterile-manufacturing requirements.
When does neomycin sulfate and polymyxin B sulfate lose exclusivity?
The core ingredients have no meaningful remaining composition-of-matter exclusivity in the United States. Neomycin and polymyxin B have been used clinically for decades, and the relevant products entered the market long before the modern generic-exclusivity framework.
| Exclusivity category |
Current commercial relevance |
| New chemical entity exclusivity |
None for these legacy ingredients |
| Orphan-drug exclusivity |
Not applicable to the broad combination market |
| Pediatric exclusivity |
No general product-level protection identified |
| New formulation exclusivity |
Possible only for a specifically approved formulation or delivery system |
| ANDA 180-day exclusivity |
May arise for an individual generic applicant after a Paragraph IV challenge |
| Patent-term extension |
Not commercially relevant to the legacy active ingredients |
A generic applicant could obtain 180-day exclusivity if it is the first eligible ANDA filer with a qualifying Paragraph IV certification. That exclusivity would apply to the specific ANDA and patent challenge, not to the active ingredients across all dosage forms.[5]
What patents protect neomycin sulfate and polymyxin B sulfate products?
The basic antibiotic combination has limited patent protection because the active ingredients and conventional uses are old. Commercial patent value would most likely arise from a specific formulation, delivery system, manufacturing process, preservative system, or new therapeutic use.
Formulation patents
Potentially relevant formulation claims could cover:
- Improved ophthalmic suspension stability
- Preservative-free multidose delivery
- Enhanced ocular residence time
- Specific viscosity or particle-size profiles
- Controlled-release ear-delivery systems
- Reduced irritation or sensitization
- Novel packaging or sterile dispensing systems
These claims must be assessed product by product. A patent on a delivery device or formulation may not block an ointment, solution, or suspension using a different composition.
Method-of-use patents
Method-of-use protection is commercially limited because the principal indications, including bacterial conjunctivitis, external otitis, and superficial bacterial infection, are longstanding. Any surviving method patent would need to cover a narrowly defined patient population, dosing regimen, resistant organism, or clinical setting.
Orange Book listings
The FDA Orange Book is the primary U.S. source for patents and regulatory exclusivities listed against approved prescription products.[5] Legacy neomycin and polymyxin B products generally have no active ingredient patents that create a broad market barrier. Patent review must distinguish among:
- Products containing only neomycin and polymyxin B.
- Products containing bacitracin.
- Products containing hydrocortisone.
- Products containing dexamethasone.
- Products with proprietary devices or delivery systems.
A patent listed against a corticosteroid combination does not automatically cover an antibiotic-only product.
Which companies are challenging neomycin and polymyxin B products?
The market is supplied primarily by generic manufacturers, contract manufacturers, and private-label distributors. Publicly visible competitive activity is usually reflected through ANDA approvals, product discontinuations, shortage notices, and wholesaler listings rather than high-profile patent litigation.
Common supplier categories include:
- Large generic pharmaceutical companies
- Ophthalmic-specialty manufacturers
- Hospital and clinic suppliers
- Contract sterile-fill manufacturers
- Retail private-label companies
- Compounding pharmacies, where legally permitted
The principal competitive threat is therefore substitution among approved generic suppliers. A company can lose share without a patent case if a competitor offers a lower price, better inventory, or more reliable wholesaler service.
What patent litigation affects neomycin sulfate and polymyxin B?
Patent litigation risk is low for the conventional combination. The ingredients are mature, and the products have a long history of generic use. Litigation risk increases in three situations:
Combination products with corticosteroids
Products containing dexamethasone or hydrocortisone may have separate formulation or use patents, although the age of these products reduces the likelihood of broad, enforceable protection.
Proprietary ophthalmic delivery systems
A sterile multidose device, preservative-free system, or controlled-delivery platform may have device or formulation claims independent of the antibiotic ingredients.
New anti-infective indications
A sponsor seeking to reposition the combination for a specialized indication could pursue method-of-use patents. Such claims would have limited impact on established generic indications unless the prescribing market shifted toward the patented use.
No broad, branded patent estate comparable to those supporting modern specialty drugs is associated with conventional neomycin sulfate and polymyxin B sulfate products.
How strong is the patent estate for neomycin and polymyxin B?
The patent estate is weak for the active ingredients and conventional dosage forms, but manufacturing and regulatory barriers remain meaningful.
| Protection factor |
Assessment |
Commercial impact |
| Composition-of-matter patents |
Very weak or expired |
Does not restrict generic entry |
| Conventional-use patents |
Weak |
Limited litigation leverage |
| Formulation patents |
Product-specific |
Can protect a narrow product |
| Sterile manufacturing capability |
Moderate barrier |
Restricts the number of reliable suppliers |
| Bioequivalence and quality requirements |
Moderate barrier |
Increases development cost and launch time |
| Supply-chain qualification |
Moderate barrier |
Makes hospital and wholesaler access important |
| Brand loyalty |
Low to moderate |
Higher in ophthalmic specialty channels |
| Pricing power |
Low |
Multiple generic substitutes constrain margins |
The main defensibility is operational rather than patent-based. A supplier with validated sterile capacity, dependable active-ingredient sourcing, and strong distribution can outperform competitors despite having little or no patent protection.
What generic entry risks exist?
Generic entry risk is already realized in the conventional market. The more relevant issue is additional generic erosion and supplier replacement.
Ophthalmic generic risks
Ophthalmic products have fewer qualified manufacturers than simple oral or topical products because sterile production is required. That reduces the number of viable competitors but does not eliminate price pressure. Once several suppliers are approved, reimbursement managers and wholesalers can shift volume quickly.
Otic generic risks
Otic products generally face broad substitution because physicians can select among multiple antibiotic and antibiotic-steroid products. A generic entrant can pressure price, particularly where the product is dispensed through retail pharmacies.
Topical generic risks
Topical products face the highest substitution risk. Retail consumers, pharmacies, hospitals, and private-label operators can choose among branded, generic, and store-brand alternatives. Product differentiation is limited unless the formulation has a meaningful tolerability or delivery advantage.
How does the market compare with modern anti-infective drugs?
Neomycin and polymyxin B occupy the low-cost end of the anti-infective market.
| Market characteristic |
Neomycin/polymyxin B |
Newer branded anti-infective |
| Patent protection |
Minimal for conventional products |
Often central to valuation |
| Pricing |
Generic and low |
Higher, especially for specialty indications |
| Prescribing driver |
Familiarity, cost, availability |
Clinical differentiation and resistance profile |
| Manufacturing |
Sterile capacity may be required |
Often more complex and tightly controlled |
| Revenue concentration |
Distributed across many suppliers |
Often concentrated in one sponsor |
| Litigation value |
Low |
Potentially high |
| Reimbursement sensitivity |
High |
Variable |
| Commercial growth |
Flat to low |
Can grow through indication expansion |
The combination is unlikely to produce the revenue trajectory of newer ophthalmic anti-infectives, branded otic products, or specialty formulations. Its financial profile is closer to a stable generic utility product.
What is the financial trajectory for neomycin sulfate and polymyxin B?
No major public company generally reports neomycin sulfate and polymyxin B as a separate revenue line. Financial analysis therefore depends on product-level prescription data, manufacturer disclosures, wholesaler data, and market-research estimates.
The expected trajectory is:
- Mature demand with limited unit growth.
- Persistent price compression in highly substituted products.
- Temporary price increases during shortages.
- Margin differences driven by manufacturing efficiency.
- Greater resilience for reliable ophthalmic suppliers than for commodity topical suppliers.
- Limited upside without a differentiated formulation, device, or new indication.
Revenue exposure
Revenue exposure is most significant for manufacturers with:
- A narrow ophthalmic portfolio
- Heavy dependence on a single sterile facility
- Hospital or government contracts
- Limited alternate suppliers
- High concentration in shortage-prone presentations
For diversified generic companies, the combination is unlikely to materially affect consolidated revenue. For a small ophthalmic manufacturer, an outage or product discontinuation can have a disproportionate effect.
Pricing and margin dynamics
The active ingredients are inexpensive relative to sterile processing, packaging, quality control, regulatory compliance, and distribution. Gross-margin pressure is therefore driven less by active pharmaceutical ingredient cost than by:
- Batch failure risk
- Sterile-fill utilization
- Container and tube costs
- Preservative and packaging requirements
- Product returns and expiration
- Wholesaler discounts
- Contract-manufacturing fees
A manufacturer with high plant utilization can maintain better economics than a smaller producer even when market prices are similar.
What geographic markets are most relevant?
The United States is commercially important because of prescription reimbursement, Orange Book substitution, and the scale of generic dispensing. Europe and other developed markets also have mature generic competition, but product approvals, naming conventions, reimbursement rules, and antibiotic stewardship policies differ by country.
Emerging markets may show stronger unit demand but lower prices and more variable regulatory enforcement. Local manufacturing and tender participation can matter more than patent ownership. A company seeking international expansion would need country-specific registrations because U.S. FDA approval does not create automatic foreign market access.
What manufacturing and intellectual-property barriers remain?
The strongest barriers are practical:
- Sterile ophthalmic manufacturing
- Validated aseptic processing
- Control of particulate contamination
- Consistent potency across active ingredients
- Compatibility with tubes, bottles, and dispensing tips
- Stability over the labeled shelf life
- Reliable sourcing of qualified neomycin and polymyxin B materials
- Pharmacovigilance for hypersensitivity and ototoxicity risks
These barriers can support temporary supply advantages but do not create durable monopoly pricing. The market remains contestable when multiple manufacturers maintain approved products and adequate capacity.
What settlement agreements affect the market?
Conventional neomycin sulfate and polymyxin B products have limited settlement activity compared with high-value branded medicines. Paragraph IV settlements are more likely to arise around a specific branded combination, formulation, or device than around the old antibiotic ingredients themselves.
Where a settlement exists, its commercial effect depends on:
- The challenged patent claims
- The generic product’s dosage form
- The agreed launch date
- Authorized-generic rights
- Supply or licensing provisions
- Whether the patent covers the active product or only a secondary feature
A settlement affecting a steroid-containing product should not be generalized to all neomycin and polymyxin B products.
What generic launch scenarios are most likely?
The most likely scenario is continued multi-source generic supply with gradual price erosion.
| Scenario |
Probability |
Market effect |
| Stable multi-source generic market |
High |
Low prices and steady demand |
| Supplier exit |
Moderate |
Short-term share gains for remaining suppliers |
| Sterile-product shortage |
Moderate |
Temporary price and volume volatility |
| New differentiated formulation |
Low |
Potential premium pricing |
| Broad patent-driven exclusion |
Very low |
Unlikely for conventional products |
| Retail private-label expansion |
Moderate |
Further pressure on topical margins |
The greatest near-term commercial risk is supply interruption, not patent expiry. The greatest upside is a differentiated delivery system or a manufacturing platform that improves availability and tolerability.
Key Takeaways
- Neomycin sulfate and polymyxin B sulfate are mature generic antibiotics with no meaningful remaining composition-of-matter exclusivity.
- The market includes ophthalmic, otic, and topical products, each with different regulatory and commercial dynamics.
- Conventional products have weak patent protection. Formulation, device, and manufacturing patents can create narrower barriers.
- Paragraph IV litigation and settlements are more relevant to specific branded combination products than to the legacy antibiotic ingredients.
- Ophthalmic products have higher manufacturing barriers because of sterile-processing requirements.
- Revenue growth is likely to be limited. Financial performance depends on supply reliability, production efficiency, reimbursement, and distribution.
- Generic entry is already established. Further competition will mainly affect price, market share, and supplier stability.
- No broad branded patent estate supports a high-value investment thesis for the conventional combination.
FAQs
Is neomycin sulfate and polymyxin B sulfate still commercially important?
Yes, but as a mature generic product. Its importance comes from recurring clinical use and broad availability rather than high pricing or patent protection.
Are neomycin and polymyxin B available over the counter?
Some topical products containing related antibiotic combinations are sold over the counter, while ophthalmic and otic prescription products remain subject to product-specific FDA labeling and approval status.
Can a generic manufacturer obtain exclusivity for this combination?
A qualifying first ANDA filer may obtain 180-day generic exclusivity after a valid Paragraph IV challenge. That protection would be product-specific and temporary.
Does a patent on neomycin and polymyxin B cover all dosage forms?
No. Patent scope depends on the claims. A patent covering an ophthalmic formulation, device, or steroid combination may not cover an otic or topical product.
What is the main investment risk in this market?
The main risk is commodity-price compression combined with manufacturing disruption. Companies with concentrated sterile capacity or weak supply reliability are more exposed than diversified generic manufacturers.
References
-
U.S. Food and Drug Administration. (n.d.). Neomycin and polymyxin B sulfates ophthalmic ointment prescribing information. FDA labeling database.
-
U.S. Food and Drug Administration. (n.d.). Neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension prescribing information. FDA labeling database.
-
U.S. Food and Drug Administration. (n.d.). Neomycin and polymyxin B sulfates and hydrocortisone otic solution prescribing information. FDA labeling database.
-
National Library of Medicine. (n.d.). DailyMed: Neomycin sulfate and polymyxin B sulfate drug labels. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
